The 4 analysts offering 12-month price forecasts for Bellerophon Therapeutics Inc have a median target of 26.00, with a high estimate of 35.00 and a low estimate of 19.00. The median estimate represents a +230.37% increase from the last price of 7.87.
The current consensus among 4 polled investment analysts is to Buy stock in Bellerophon Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.91
Reporting Date Mar 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.